370 A first-in-human phase 1/1b study of receptor tyrosine kinase (RTK) inhibitor, MGCD, in patients with advanced solid tumors. (September 2015) - Schwartz, G.; Adkins, D.; Heist, R.; Werner, T.; Abbott, M.; Barber, S.; Slusarz, K.; Agarwal, N.; Neuteboom, S.; Faltaos, D.; Chen, I.; Christensen, J.; et al.